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Abstract
Brucellosis is a highly contagious zoonosis affecting livestock and human beings. The human disease lacks pathognomonic
symptoms and laboratory tests are essential for its diagnosis. However, most tests are difficult to implement in the areas and
countries were brucellosis is endemic. Here, we compared the simple and cheap Rose Bengal Test (RBT) with serum
agglutination, Coombs, competitive ELISA, Brucellacapt, lateral flow immunochromatography for IgM and IgG detection
and immunoprecipitation with Brucella proteins. We tested 208 sera from patients with brucellosis proved by bacteriological
isolation, 20 contacts with no brucellosis, and 1559 sera of persons with no recent contact or brucellosis symptoms. RBT was
highly sensitive in acute and long evolution brucellosis cases and this related to its ability to detect IgM, IgG and IgA, to the
absence of prozones, and to the agglutinating activity of blocking IgA at the pH of the test. RBT was also highly specific in
the sera of persons with no contact with Brucella. No test in this study outperformed RBT, and none was fully satisfactory in
distinguishing contacts from infected patients. When modified to test serum dilutions, a diagnostic titer .4 in RBT resulted
in 87.4% sensitivity (infected patients) and 100% specificity (contacts). We discuss the limitations of serological tests in the
diagnosis of human brucellosis, particularly in the more chronic forms, and conclude that simplicity and affordability of RBT
make it close to the ideal test for small and understaffed hospitals and laboratories.
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Introduction
Brucellosis is a highly contagious zoonosis caused by the Gram-
negative bacteria of the genus Brucella. B. abortus, B. suis and
B. melitensis, three of the so-called smooth (S) brucellae,
preferentially infect cattle, swine and sheep and goats, respectively.
These animals are the source of most cases of human brucellosis, a
grave and debilitating disease that may leave disabling sequelae.
Its incidence is very high in some countries of the Mediterranean
basin and bordering areas and, in all likelihood, in developing
countries throughout the world. The reported incidence in these
countries varies widely (from ,0.01 to .200 per 100,000),
reflecting the difficulties in recognizing a disease that lacks
pathognomonic symptoms [1,2]. This absence of specific symp-
toms makes it difficult to distinguish brucellosis from several febrile
conditions that often occur in the same areas, including malaria
[3–11] so that laboratory tests are essential for diagnosis [12].
Among these tests, only the isolation of the microorganism
provides absolute proof of infection but bacteriological diagnosis is
expensive and dangerous. On the other hand, serological tests are
easier to implement and a great aid in diagnosis. The humoral
immunoresponse to S brucellae is dominated by antibodies to the
polysaccharide (PS) section of the Brucella S lipopolysaccharide
(S-LPS) and it shows a typical IgM/IgG (and IgA) shift. In acute
cases (i.e., short evolution) IgM is present in the serum; then this
immunoglobulin returns progressively to background levels, so
that IgG (and IgA) are dominant in the sera of long evolution (i.e.
chronic) patients before treatment. Moreover, non-agglutinating
antibodies (detected in the Coombs test) increase over agglutinat-
ing antibodies (active in the classical serum agglutination test
[SAT]) during the course of the infection [12,13]. Accordingly, the
SAT-Coombs combination has been classically used both to
increase sensitivity and to evaluate the stage of evolution of the
infection. Other S-LPS (or PS) tests proposed more recently
include the lateral flow immunochromatography assay (LFiC) for
IgM and IgG assessment, a fluorescence polarization assay, a
variety of indirect ELISA, and the immunocapture Brucellacapt
test (for a recent review, see [14]). In addition, a competitive
ELISA (cELISA) has been proposed [15]. Because these tests
require well equipped laboratories and/or adequate budgets, they
cannot be implemented in many laboratories in endemic areas.
The Rose Bengal test (RBT) is a rapid slide-type agglutination
assay performed with a stained B. abortus suspension at pH 3.6–3.7
and plain serum. Because of its simplicity, it is often used as a
screening test in human brucellosis and would be optimal for small
laboratories with limited means. However, there is confusion
about the value of this test so that present WHO guidelines
recommend that RBT results be confirmed by other tests [14,16].
Points of concern expressed by several authors include low
sensitivity [17] particularly in long evolution (chronic) cases
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[18,19] and relatively low specificity in endemic areas [20,21].
Moreover, some authors consider that prozones make strongly
positive sera appear as negative in RBT [22]. In the present work,
we have addressed these points and reexamined the usefulness of
RBT for the diagnosis of human brucellosis using sera of patients
with no brucellosis, culture-positive brucellosis patients, and
healthy persons that had had contact with the pathogen.
Materials and Methods
Ethical statement
The sera used in this work were obtained during clinical
practice in the 1975–2001 period. Their use in this research was
approved by the Ethical Boards of Clı´nica Universidad de Navarra
(Pamplona, Spain), Hospital de Navarra (Pamplona, Spain),
Hospital Universitari de Bellvitge (Barcelona, Spain), Hospital
Clı´nico Universitario Virgen de la Victoria (Ma´laga, Spain),
Hospital de la Inmaculada de Hue´rcal-Overa (Almerı´a, Spain),
Hospital General Universitario de Albacete (Albacete, Spain), and
Hospital Clı´nico Universitario de Valladolid (Valladolid, Spain).
Serological tests
For RBT, 30 mL of plain serum were dispensed on a white
glossy ceramic tile and mixed with an equal volume of RBT
antigen (Veterinary Laboratory Agency; England, United King-
dom; http://www.defra.gov.uk/vla/) (previously equilibrated at
room temperature and shaken to resuspend any bacterial
sediment) using a toothpick. The tile was then rocked at room
temperature for 8 minutes (instead of the 4 minutes recommended
for animal brucellosis [23]), and any visible agglutination and/or
the appearance of a typical rim [23] (Figure S1) was taken as a
positive result. Positive sera were tested further as follows. Eight
30 mL drops of saline were dispensed on the tile and the first one
mixed with an equal volume of the positive plain serum (1/2
serum dilution). Then, 30 mL of this first dilution were transferred
to the second drop with the help of a micropipette and mixed to
obtain the 1/4 dilution. From this, the 1/8 to 1/128 dilutions were
obtained by successive transfers and mixings taking care of rinsing
the pipette tip between transfers. Finally, each drop was tested
with an equal volume (30 mL) of the RBT reagent, so that the final
dilutions ranged from 1/4 to 1/256. The SAT and Coombs test in
microtitter plates, Brucellacapt (Vircell S.L, Santa Fe, Granada,
Spain) and LFiC (kindly provided by Dr. H. Smits, KIT
Biomedical Research, Royal Tropical Institute/Koninklijk Insti-
tuut voor de Tropen, Amsterdam, The Netherlands) were
performed as described before [24,25]. For the Coombs test, a
titer $ two times the SAT titer in the same serum was considered
as positive. In some cases (see Results), SAT was also performed in
the citrate buffer (pH 5) provided as diluent in the Brucellacapt kit.
To this end, the bacteria in a volume of the SAT suspension were
collected by centrifugation, washed with citrate buffer and
resuspended in an equal volume of the same buffer. cELISA was
performed according to the instructions of the manufacturer
(Svanova Biotech, Uppsala, Sweden). Antibodies to Brucella
proteins were detected by counterimmunoelectrophoresis (CIEP)
using an S-LPS free extract obtained from a B. melitensis rough
mutant [26].
Human sera
The following groups of sera were used: (i), two hundred and
eight sera of an equal number of patients with brucellosis
confirmed by bacteriological culture (all B. melitensis) that were
diagnosed at the above-mentioned institutions in the 1975–2001
period; a subset of patients in this group for which the IgM and
IgG profile could be determined (by LFiC) were classified as short
(IgM dominant) or longer evolution (IgG dominant with low or no
IgM) (see Results) and correspond broadly to the concepts of acute
and chronic brucellosis; (ii), the sera of 20 persons (Table 1 in
Supporting Information S1) that had had professional contact
(veterinarians, slaughter house workers, shepherds, etc.) with
Author Summary
The Rose Bengal Test (RBT) for brucellosis serological
diagnosis was adapted to test serum dilutions and its
usefulness evaluated using sera of Brucella culture positive
patients, persons with contact with Brucella but no
symptoms, veterinarians accidentally injected with vaccine
Rev 1 who had not developed the disease and normal
persons. Using the standard protocol, RBT was not
outperformed by more sophisticated and expensive tests
(serum agglutination, Coombs, competitive ELISA, Brucel-
lacapt, and lateral flow immunochromatography for IgM
and IgG detection) in identifying Brucella infected patients.
All tests failed to discriminate with total specificity the sera
from contacts or Rev 1 injected individuals. However, none
of these sera was positive in the modified RBT adapted to
test serum dilutions at titers higher than 1.4. When there
is suspicion of brucellosis, RBT is recommended as the first
test and, depending upon the titer, a positive result does
not need confirmation by other (usually more expensive,
sophisticated and time consuming) tests.
Table 1. Results of SAT and RBT in patients (n = 208) with brucellosis proved by bacteriological culture.1
SAT
N6 of positive sera using the
standard RBT protocol (%) N6 of RBT positive (%) at titers:
2
Titer N6 of sera #4 $8
#1:20 6 6 (100) 2 (0,96) 4 (1,92)
$1:40 202 202 (100) 26 (12,5) 176 (85,5)
$1:80 201 201 (100) 25 (12,0) 176 (85,0)
$1:60 185 185 (100) 13 (6,20) 172 (83,0)
$1:320 160 160 (100) 2 (0,90) 158 (76,3)
$1:640 136 136 (100) 0 (0,00) 136 (65,7)
1Sera were collected from patients with brucellosis proved by blood (n = 205) or abscess (n = 3) culture.
2Titers correspond to plain serum (titer 1:2) or serum dilutions made in phosphate buffered saline and then tested with an equal volume of RBT regent (1:4, etc.).
doi:10.1371/journal.pntd.0000950.t001
Human Brucellosis Serodiagnosis
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B. melitensis-infected animals or their products or had accidentally
injected themselves with vaccine B. melitensis Rev 1 and that were
followed for a period of at least two years; (iii), eleven sera from
brucellosis patients that had been collected in a different study
because they showed the prozone effect; and (iv), one thousand five
hundred and fifty-nine sera from patients with no symptoms of
brucellosis sent to the laboratory for the serological diagnosis of
other infections. The sera were aliquoted and kept frozen at
220uC. Care was taken not to thaw and freeze repeatedly these
sera. Controls showed no deterioration under these conditions.
Results
The 1559 sera from patients with no brucellosis yielded only
one positive result in the standard RBT. The patient was
asymptomatic and re-examination of the medical history showed
that he had suffered from brucellosis in the past. The sera of 19 of
the 20 persons that had had professional contact with B. melitensis-
infected animals or had accidentally injected themselves with
vaccine Rev 1 showed reactions in the standard RBT despite the
fact that these persons were consistently asymptomatic. None of
these sera, however, had a titer .1:4 when tested in the modified
RBT (Table 1 in Supporting Information S1). In one case (C-20,
Table 1 in Supporting Information S1), seroconversion was
observed at the time when symptoms compatible with brucellosis
developed, and this patient was successfully treated with
antibiotics. Concerning other tests, 3 of these 20 persons had
SAT titers equal to 160, 8 had Brucellacapt titers $320, 16 had a
positive Coombs, 4 and 8 were LFiC-IgM and -IgG positive,
respectively, and 5 showed antibodies to cytosolic proteins.
Table 1 compares the results of SAT and RBT obtained with
the sera of the 208 culture positive patients. Whereas 185 had SAT
titers $160, the standard RBT identified as positive all the 208
sera. When performed on serum dilutions, a RBT titer
discriminating all healthy contacts ($1:8; previous paragraph)
would identify correctly 180 sera of the culture positive patients
(176+4; Table 1; 87.4% sensitivity). A SAT titer similarly
discriminating all healthy contacts (.1:160; previous paragraph)
would identify only160 of these patients (76.9% sensitivity). In
those cases that could be studied with more detail, RBT titers
varied from 4 to 256 in the sera with weak or negative Coombs
and anti-S-LPS IgM but no IgG, and from 4 to 128 in the sera
with a positive Coombs and anti-S-LPS IgG stronger than IgM
(Tables 2 and 3 in Supporting Information S1).
The 23 sera (208 -185) of culture positive patients with SAT
titers ,160 included 6 showing the blocking phenomenon. This is
a rare event appearing in some prolonged brucellosis cases when
non-agglutinating IgA are in amounts higher than other anti-S-
LPS antibodies and it represents the extreme case of prozones [27–
30]. Table 2 shows that neither RBT nor Brucellacapt were
affected by the blocking phenomenon and that, as expected, SAT
titers increased upon IgA removal. Since RBT and Brucellacapt
have in common the use of acid buffers (pH 3.65 and 5.0,
respectively), we hypothesized that an acid pH could promote
agglutination and overcome the presence of blocking IgA. To test
this, we substituted citrate buffer pH 5.0 for the saline in the
standard SAT bacterial suspension (see Material and Methods).
Under these conditions, the blocking activity in SAT disappeared.
To confirm that the use of an acid buffer removes the
agglutination-inhibitory effect of IgA and accounts for the absence
of prozones in RBT, we examined 11 sera showing 1/40 to 1/80
prozones. These prozones disappeared upon absorption with anti-
IgA and were not observed in SAT at pH 5, RBT or Brucellacapt.
Of the 23 sera with SAT titers,160, 2 (nus 1 and 4, Table 2) and
17 (nus 7 to 23, Table 3) had RBT titers#4. Using these 23 sera and
those of the 20 persons that had had professional contact with B.
melitensis-infected animals or had accidentally injected themselves with
vaccine Rev 1 (see above), we examined whether other tests could
complement RBT and discriminate the sera of infected patients from
those of healthy contacts (Table 1 in Supporting Information S1).
The numbers of false positives/false negatives were: CIEP-proteins,
5/4; LFiC-IgM, 4/13; LFiC-IgG, 12/5; Brucellacapt ($1:640), 2/2;
and Coombs ($two times the corresponding SAT titer) 18/1, and
cELISA (cut-off at 30% inhibition) 8/0.
Finally, 11 culture positive patients could be followed
periodically. SAT, LFiC-IgM, LFiC-IgG and RBT became
negative between months 1 and 16 after the beginning of a
successful antibiotic treatment. However, 4 and 2 of these patients
remained positive in Coombs, and cELISA, respectively, and 2
had Brucellacapt titers equal to 1:320. Although greatly dimin-
ished in titer and number of precipitin lines, 6 patients remained
positive in CIEP (a single precipitin line in all cases).
Table 2. Results of serological tests with sera showing the SAT blocking phenomenon.1
Reciprocal of serum titers in:
SAT LFiC2 CIEP-proteins3
Patient N6 RBT pH 74 pH 7, IgA- absorbed5 pH 56 Brucellacapt Coombs-IgG IgM IgG
1. 4 ,20 40 160 640 1280 0 2 4 (3)
2. 16 ,20 160 640 5120 10240 0 3 64 (4)
3. 16 ,20 40 640 5120 20480 0 4 32 (5)
4. 2 ,20 20 160 640 2560 0 3 16 (3)
5. 32 ,20 ND7 1280 10240 40960 0 4 64 (8)
6. 8 ,20 320 ND7 ND7 20480 0 ND7 8 (3)
1Sera were collected from patients with brucellosis proved by blood (n = 5) or abscess (n = 1) culture.
2From 0 (negative) to 4 (strong positive).
3Reciprocal of serum titers (number of precipitin lines).
4Standard SAT with antigen and serum dilutions in PBS pH 7.
5SAT performed in PBS pH 7.0 using serum deprived of IgA by absorption with anti-human IgA rabbit serum.
6SAT performed with antigen resuspended in citrate pH 5 and serum dilutions in the same buffer.
7ND, not done.
doi:10.1371/journal.pntd.0000950.t002
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Discussion
One of the early findings in brucellosis was the observation that
the sera of infected individuals contained agglutinating antibodies
that could be detected in SAT. This test was soon adapted to the
more practical slide-agglutination format but this method was
prone to false negative results because of prozones and blocking
and non agglutinating antibodies [31]. We show here that RBT
overcomes these three problems. Moreover, we confirm that it is
highly sensitive and demonstrate that a simple adaptation to test
serum dilutions improves its specificity and considerably reduces
the need for additional serological tests. This simple modification
makes RBT close to the ideal test for small laboratories.
Although the overall sensitivity reported for RBT varies widely,
there could be several reasons for this. Variations in sensitivity
have been demonstrated in the past for RBT antigens of various
sources [32,33] and the use of good quality antigens made by
experienced or reference laboratories is of the utmost importance.
Although this has been occasionally considered as a weakness of
RBT [14], it is well know that a good quality control is necessary
in all brucellosis serological tests because of the tendency of S
brucellae to dissociate into rough variants lacking the diagnosti-
cally significant S-LPS epitopes [23]. Also, the use of white opaque
glossy surfaces is important [34], and awareness of the various
agglutination patterns (Figure S1a proper incubation time is
critical. With regard to the latter, the literature shows from 2 to
5 minutes [20,34,35]. However, it has been known for a long time
[36] that some human sera require a longer incubation to become
positive in the RBT-like card test. In our experience, sera without
blocking antibodies or prozones are strongly positive in less than
4 minutes, but sera with blocking IgA or with high titers of non-
agglutinating antibodies (high Coombs titers) may need up to
8 minutes to develop the bacterial clumps or the characteristic
rim. These antibodies are typical of long evolution brucellosis and,
therefore, the low sensitivity (54 to 61%) reported in chronic
brucellosis by some authors [18,19] could be accounted for by a
non optimized RBT protocol. Our results clearly show that RBT
was equally useful in the IgM-negative (longer evolution) and IgM-
positive (shorter evolution) groups of patients and that the use of an
acidic pH abrogates prozones and blocking phenomena.
Consistent with the demonstration that RBT detects both S-
LPS specific IgM, IgG and IgA and that neither prozones nor
blocking antibodies are sources of false negative results, most
authors have reported a high sensitivity in culture-positive patients,
equal or better than that of SAT, ELISA-IgG, ELISA-IgM, or
LFiC for IgM plus IgG [20,37–39]. In this work, we have also used
the sera of culture positive patients as the reference, and this point
deserves attention for a correct understanding of our results in a
clinical context. Careful studies with appropriate bacteriological
procedures have shown that the rate of success in isolating Brucella
is higher during the initial disease than in relapses (c.a. 80 versus
65%, respectively, in ref. [40]) and lowest in the more chronic
forms [41]. The reasons for this consistent observation are not
understood but, as illustrated for the case of hepatosplenic
abscesses [25,41], it is in a fraction of the more chronic cases
where serology (by RBT or other tests) and culture are sometimes
not conclusive. Indeed, the scarce RBT negative results that have
been well documented correspond to a few patients with focal
forms of brucellosis [25,41–43]. In these difficult cases, a
combination of serological tests and clinical findings and a careful
follow-up of the patients are in order. The evidence obtained in a
limited number of these cases suggests that the Coombs test
Table 3. Results with sera showing SAT titers ,1:160 and no blocking phenomenon.1
Patient N6 Serum titers: LFiC
2
RBT SAT Brucellacapt Coombs-IgG cELISA %3 IgM IgG CIEP-proteins4
7. 4 80 ND 80 ND5 2 ND5 0
8. 2 40 640 320 35 2 0 1 (1)
9. 4 80 640 640 42 2 0 4 (2)
10. 2 80 640 320 45 2 1 1 (1)
11. 4 80 640 640 35 1 2 8 (3)
12. 4 80 640 1280 51 1 2 4 (2)
13. 4 80 640 1280 53 1 2 8 (1)
14. 4 40 40960 20480 95 +/2 3 2 (1)
15. 2 40 320 160 55 0 0 0
16. 4 80 1280 640 32 0 0 8 (1)
17. 2 40 320 2560 55 0 0 0
18. 4 80 640 1280 38 0 1 0
19. 2 80 640 1280 39 0 2 16 (4)
20. 2 40 5120 10240 ND5 0 3 16 (4)
21. 4 80 2560 10240 75 0 3 32 (4)
22. 4 80 ND 320 ND5 ND5 ND5 1 (1)
23. 2 80 ND 2560 ND ND ND5 ND5 16 (3)
1Sera were collected from patients with brucellosis proved by blood (n = 15) or abscess (n = 2) culture.
2From 0 (negative) to 4 (strong positive).
3% competitive index.
4Serum titers (number of precipitin lines).
5ND, not done.
doi:10.1371/journal.pntd.0000950.t003
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provides the best indication of the seroconversion that parallels the
relapses and the evolution during treatment [25,44] (see also
below).
The specificity of the RBT and other S-LPS tests is also worth
commenting on. Febrile conditions including tuberculosis, malar-
ia, typhoid fever, Still’s disease, lupus erythematosus, rheumatoid
arthritis, sarcoidosis, and active lymphoma are not a source of
RBT false positive results [5]. On the other hand, S-LPS cross-
reactivity with Vibrio cholerae, Francisella tularensis and Yersinia
enterocolitica 0:9 is a potential source of unspecific results in all
S-LPS tests. However, this is of little importance in clinical
practice. Although positive cases have been reported in V. cholerae
vaccinated individuals [45,46], there are no RBT observations in
cholera patients and this illustrates that the clinical picture is
widely different. With regard to tularemia, in a series of 5 patients,
3 were RBT positive (T. Marroda´n, Ph. Thesis, University of
Navarra, Spain) but these were easily differentiated by the clinical
picture and other tests. Yersiniosis by Y. enterocolitica O:9 elicits
antibodies that react in all Brucella S-LPS tests including RBT
[26,47] but there are tests with protein antigens that discriminate
Y. enterocolitica O:9 and S Brucella infections [26] (see also below).
Indeed, antibodies to Brucella S-LPS persist for protracted periods
in a percentage of recovered patients in all S-LPS tests [13].
Therefore, a past history of brucellosis is a cause of unspecific
serological results that has to be evaluated by the physician.
Finally, some authors consider that RBT has a limited usefulness
in endemic areas [20,21]. However, Ruiz-Mesa et al. [48]
compared the sera of individuals that had had repeated contact
with Brucella with those with no regular exposure or history of
brucellosis, and reported specificities of 91.7 and 94.3%. This
same problem was addressed by Go´mez et al. [39] who found 100
and 97% sensitivity and specificity, respectively. These studies
indicate that the specificity problem of the standard RBT is not so
critical and that, as illustrated by our results, other S-LPS tests are
also affected. In this regard, it is important to stress that the
diagnosis of human brucellosis has to be made on the basis of
compatible symptoms, clinical findings and a thorough anamnesis,
that it cannot rely exclusively on a weak positive result in any
S-LPS serological test and that there are no cut-off diagnostic titers
in any single S-LPS test. An alternative to S-LPS tests is the use of
Figure 1. Proposed use of RBT in the diagnosis of human brucellosis and complementary tests.
doi:10.1371/journal.pntd.0000950.g001
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protein tests [12]. It has been known for a long time that a large
proportion of brucellosis patients develop antibodies to soluble
Brucella proteins [26]. However, in the present study, 5 of the 20
healthy persons that had had professional contact with infected
livestock developed anti-protein antibodies (Table 1 in Supporting
Information S1). Recently, a large number of Brucella proteins have
been evaluated by Liang et al. [49] using brucellosis patients that
were culture and RBT-positive and had SAT titers $1:160 as well
as healthy persons. For a combination of the 5 top serodiagnostic
proteins, these authors reported a specificity of 96% (95%
sensitivity, both values optimized by ROC analysis). Although
further studies are necessary to reach a definite conclusion, these
data suggest that protein antigens may not completely solve the
specificity problems in human brucellosis serodiagnosis.
In summary, when complemented with appropriate anamnesis
and clinical findings, RBT is a very useful test for the diagnosis of
human brucellosis. It needs no complicated infrastructure or
sophisticated training, it is exceedingly cheap, highly sensitive and
easily adaptable to test serum dilutions. On these bases, a simple
scheme for the diagnosis of human brucellosis can be proposed
that could avoid confirmation of a large proportion of positive
results in the standard RBT protocol (i.e., those RBT titers $1:8)
(Figure 1). If an assessment of the stage of evolution of a particular
case is necessary, a complementary test assessing IgM and IgG
levels could be used, and for this purpose the simple LFiC seems
the appropriate complement to RBT in small laboratories. Indeed,
it is not possible to predict the proportion of RBT results that need
confirmation (RBT titers ,1:8; Figure 1) in a given population but
it is expected that long evolution cases with low levels of antibodies
in RBT or other S-LPS tests would be more common in endemic
areas with no adequate awareness of the human disease. As
stressed above, these cases would need a careful assessment by
physicians, and further serological studies in well equipped
laboratories using tests like Coombs or Brucellacapt. Moreover,
culture should be attempted because, even though its sensitivity is
low in these cases, a positive result is a definite proof of infection.
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